Kampo medicines, Rokumigan, Hachimijiogan, and Goshajinkigan, significantly inhibit glucagon-induced CREB activation

The pathophysiology of type 2 diabetes mellitus (T2DM) is characterized by not only insulin resistance, but also the abnormal regulation of glucagon secretion, suggesting that antagonizing the glucagon-induced signaling pathway has therapeutic potential in the treatment of T2DM. Although various Kam...

Descripción completa

Detalles Bibliográficos
Autores principales: Funakoshi-Tago, Megumi, Yu, Seisho, Kushida, Akira, Takeuchi, Kazusane, Tamura, Hiroomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090351/
https://www.ncbi.nlm.nih.gov/pubmed/32215330
http://dx.doi.org/10.1016/j.heliyon.2020.e03598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090351/
https://www.ncbi.nlm.nih.gov/pubmed/32215330
http://dx.doi.org/10.1016/j.heliyon.2020.e03598

Ejemplares similares